StageZero Life Sciences Ltd
TSX:SZLS
StageZero Life Sciences Ltd
TSX:SZLS
Price:
0.04
CAD
Market Closed
Market Cap:
CA$4.9m
Relative Value
The Relative Value of one
SZLS
stock under the Base Case scenario is
0.09
CAD.
Compared to the current market price of 0.04 CAD,
StageZero Life Sciences Ltd
is
Undervalued by 57%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SZLS
Relative Value
Base Case
0.09
CAD
Undervaluation 57%
Multiples Across Competitors
SZLS Competitors Multiples
StageZero Life Sciences Ltd Competitors
StageZero Life Sciences Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
StageZero Life Sciences Ltd
TSX:SZLS
|
4.9m CAD | 2.6 | -2.5 | -3.2 | -3.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.8B USD | 6.6 | 168.6 | 16.3 | 23.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.7B USD | 5.5 | 26.3 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188B USD | 6.4 | 22.1 | 15 | 15 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119B USD | 9.9 | 30.1 | 23 | 24 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.8 | 18.3 | 13.9 | 15.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD | 3.3 | 17.2 | 11.8 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR | 14.6 | 34.4 | 59.1 | 60.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
